
 --------- 
myrtle.potter:dainippon_sumitomo_pharma_PR0_03-08-2022_00_00.pdf
Supplementary Financial Data (IFRS) forthe First Quarter of the Year Ending March 31, 2023

 --------- 
elt.elt:Novavax Announces Initiation of Phase 2b/3 Hummingbird(tm) Global Clinical Trial for the Novavax COVID-19 Vaccine in Children Aged Six Months Through 11 Years - Aug 4, 2022
Amgen data on KRAS cancer drug disappoints, opening door for rival Mirati | BioPharma Dive Amgen data on KRAS cancer drug disappoints, opening door for rival Mirati
Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology
bluebird bio reveals plans to launch two gene therapies
Trial of novel abiraterone formulation for prostate cancer completes enrollment

 --------- 
vant.vant:Judge Won't Toss $950M COVID-19 Vax Trade Secrets Row
With 'bold experiment' in drug pricing, Arcutis aims to stand out in plaque psoriasis
The Effect of Dienogest vs. Norethindrone Acetate Treatment in Endometriosis - Full Text View - ClinicalTrials.gov
Arbutus Reports Second Quarter 2022 Financial Results and Provides Corporate Update

 --------- 
myovant.myovant:Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE(r), a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis | Pfizer

 --------- 
aces.aces:REGENXBIO's MPSII Gene Therapy Charts Course to Approval
PAH Patients Prefer Yutrepia Over Tyvaso in INSPIRE Study
FDA Issues Second CRL for Pimavanserin for the Treatment of Alzheimer Disease Psychosis
BMS' plan to move Opdivo into adjuvant RCC gets knocked back
Krystal Biotech Receives FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical Trial
Sumitomo Pharma Oncology Receives Orphan Drug Designation for DSP-5336, an Investigational Menin and Mixed-Lineage Leukemia Binding Protein for Treatment of Acute Myeloid Leukemia
Pfizer to discontinue Phase III trial of dilated cardiomyopathy therapy
Sarepta Therapeutics Announces Intent to Submit an Accelerated Approval Biologics License Application for its Gene Therapy SRP-9001 to Treat Duchenne Muscular Dystrophy
UPDATED: After nearly a decade of work, AstraZeneca axes WEE1 and culls Moderna-partnered drug
Structure Therapeutics Closes $33 Million for Novel Small Molecule Drugs
U.S. Prescription Drug Market Lacks Certain Competitive Features: Case Of Biosimilars
Democrats Try to Go Big on Insulin Changes for Drug-Pricing Bill

 --------- 
mark_niemaszek.mark_niemaszek:5 Ways The Pandemic May Have Impacted Your Bladder | Well+Good

 --------- 
yuval_harel.yuval_harel:Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain.
Psychiatric adverse events in three Phase III trials of eslicarbazepine acetate for focal seizures.

 --------- 
masato_yabuki.masato_yabuki:Bone morphogenetic protein 4 rescues the bone regenerative potential of old muscle-derived stem cells via regulation of cell cycle inhibitors.
Aligos Therapeutics Initiates 12-Week Dosing Cohort in Phase 1b Study Evaluating Its Class II Capsid Assembly Modulator, ALG-000184 | Aligos Therapeutics

 --------- 
Urovant Corporate Communications:Dr. Mohit Khera on new men's health coalition
Twenty-three Georgia Urology physicians receive Top Doctors honors in Atlanta magazine
5 Ways The Pandemic May Have Impacted Your Bladder | Well+Good

 --------- 
Missing:
